S18-000003

S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt), with an IC50 of 50>10 μM) . S18-000003 can be used for the research of psoriasis with low risk of thymic aberrations[1][2].

Product Specifications

CAS Number

[2068119-11-7]

Product Name Alternative

Stibogluconate (trisodium nonahydrate)

UNSPSC

12352005

Target

ROR

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/s18-000003.html

Purity

99.31

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

FC1=C(NC(C(C)(C)C2=CC=C(NC(CC3=CC=C(S(CC)(=O)=O)C=C3)=O)C=C2F)=O)C=CC(F)=C1

Molecular Formula

C26H25F3N2O4S

Molecular Weight

518.55

References & Citations

[1]Sasaki Y, et, al. Discovery of a potent orally bioavailable retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitor, S18-000003. Bioorg Med Chem Lett. 2018 Dec 1;28 (22) :3549-3553.|[2]Imura C, et, al. A novel RORγt inhibitor is a potential therapeutic agent for the topical treatment of psoriasis with low risk of thymic aberrations. J Dermatol Sci. 2019 Mar;93 (3) :176-185.